TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06623929

Intervention type: DRUG
Intervention: Etofenamat
Description: E group: Etofenamate spray 100 mg/ml is applied to the painful area from a distance of approximately 10-15 cm in a maximum of 7 puffs. Each puff contains 18 mg etofenamate.

Intervention type: DRUG
Intervention: Diclofenac
Description: Group D: Diclofenac diethylammonium 1% spray was applied to the painful area from a distance of approximately 10-15 cm in a maximum of 6 puffs. Each puff contained 5.8 mg diclofenac diethylammonium.
Study: NCT06624254

Intervention type: OTHER
Intervention: lung mechanics, respiratory drive and effort
Description: Patient lung mechanics and respiratory drive and effort will be measured
Study: NCT06623604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Physical activity program
Description: In consultation with school administrators and classroom teachers, a physical activity program was implemented so that students\&amp;#39; classes would not be disrupted.~The exercises were carried out three days a week for 30 minutes in the school garden and gym by the same researcher, and the education was carried out in the classrooms one day a week.~During the program, students did a total of 180 hours of physical activity.
Study: NCT06619678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8507
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: Oral administration
Study: NCT06618833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of medical data
Description: Collection of medical data focused on the history of atrial fibrillation by the principal investigator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collection of global health elements
Description: Collection of global health elements (physical and mental) by the principal investigator by discussion with the patient

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMIS global questionnaire
Description: The patient completes the global PROMIS questionnaire which collects data on their overall health.~The questionnaire consists of 10 questions about the patient\&#39;s overall health, and for each question, the patient has a possible choice of 5 answers varying between different propositions depending on the question:~Excellent to poor or Totally to not at all, or Always to never or None to very intense

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collection of sociological data
Description: Collection of patient sociological data (territorial, economic, professional, ethnic) by the principal investigator
Study: NCT06631482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maintain HPI < 85
Description: Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintain MAP>=73
Description: Protocolized treatment with fluid administration, norepinephrine, and dobutamine to prevent intraoperative hypotension. The two arms are triggered by different alarms: one from a traditional monitor with an elevated MAP threshold of 73 mmHg, and the other from an HPI threshold of 85.
Study: NCT06629233

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tumor resection
Description: As the standard of care, estrogen receptor-positive breast tumors are surgically resected. From these resected tumors, small samples of both cancer tissue and healthy surrounding tissue will be analyzed using our patented Tn-Miner workflow to discover novel tumor-specific epitopes.
Study: NCT06619301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin Glargine is regularly used outside of pregnancy and its efficacy is well documented. It is a current medication we regularly use in pregnancy, however, there is limited data for comparison to the standard, NPH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Insulin NPH is a current medication used in pregnancy for diabetes mellitus. It has been used as the standard form of insulin.
Study: NCT05637970

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perclose
Description: Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perclose
Description: Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Statseal
Description: Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manualpressure will be held for at least five minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held. This will be continued until the patient has no bleeding.
Study: NCT05606315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Description: NS 50ML + Remimazolam besylate(50mg , 2mg:2ml), IV-Pump,maintenance dose 0.5-3mg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (50ml, 0.5g), IV-Pump, maintenance dose 0.3-4.0mg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (10mg,2ml), IV-Pump, maintenance dose 0.02-0.1mg/kg/h.
Study: NCT06102031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReDS-Guided
Description: ReDS™ measurements will be shared with the treating clinicians to guide diuretic treatment when discharge, home visit and outpatient follow-up, but blinded to the subjects.~At discharge:① If the ReDS™ reading \<36%, discharge as planned; ②ReDS™ reading ≥36%, increase the oral diuretic dose, discharge as planned.~When home visit and outpatient follow-up: ① If the ReDS™ reading \<20%, hold diuretics; ② If the ReDS™ reading was between 21-35%, maintain current diuretic dose and optimize GDMT. If the ReDS™ change ≥ 6% from the previous one, increase diuretic dose and optimize the GDMT; ③ If the ReDS™ reading was between 36-45%, increase diuretics and optimize the GDMT, then repeat ReDS™ test after 1 week(home visit); ④ If the ReDS™ reading was above 46%, consider intravenous diuretic therapy, and repeat ReDS™ test after 1 week(home visit) or hospitalization.
Study: NCT06095518

Intervention type: DIAGNOSTIC_TEST
Intervention: DIC markers and Thrombin Generation Parameters
Description: Observation of DIC markers and thrombin generation parameters in patients with and without thrombotic and hemorrhagic complications

Intervention type: DIAGNOSTIC_TEST
Intervention: DIC markers and Thrombin Generation Parameters
Description: Observation of DIC markers and thrombin generation parameters in patients with and without thrombotic and hemorrhagic complications
Study: NCT05844033

Intervention type: OTHER
Intervention: Screening
Description: Blood tests
Study: NCT05317377

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: Structured exercises focused on hand functionality

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Based Exergame
Description: Appropriate games from Leap Motion Based Exergame system focused on hand functionality
Study: NCT06245499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aging Brain Care Virtual Program
Description: The program involves a virtual intervention to be delivered by RN or SW care coordinators over one year. Every care partner will receive monthly virtual visits during the first 3 months and then quarterly or more depending on assessed need. The intervention relies on a tailored approach in which patient and caregiver needs are identified during visits using validated assessment tools and addressed with standardized protocols. Protocols include management of behavioral/psychological symptoms of dementia, caregiver stress, medication management, comorbidity management and advance care planning.
Study: NCT06102031

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: ReDS measurements will not be shared with the treating clinicians and the subjects, diuretic treatment will only be guided using standard clinical care.
Study: NCT03935464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUMA
Description: Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their adherence with provision of standard adherence counseling.
Study: NCT06453018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positional device, Rematee Bumper Belt or Night Shift
Description: Positional device, Rematee Bumper Belt (Rematee, Blaine, Washington), or Night Shift (Advanced Brain Monitoring) on chest belt, will be used as the intervention
Study: NCT05482256

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Esophageal String Test (EST)
Description: Non-invasive, FDA-registered sampling method to evaluate eosinophilic inflammation in the esophagus. The EST is performed by having an individual swallow a capsule attached to a string which captures secretions from the esophagus. The end of the string is taped to the cheek and the capsule is swallowed with water. After 1 hour, the EST will be removed, and the string will be processed for laboratory analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate
Description: 2 grams of toothpaste (pea sized amount) for 2 minutes

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High Resolution Esophageal Manometry (HREM)
Description: Thin flexible tube with sensors placed in the nose and swallowed for esophagus placement to conduct reading regarding the lining of the esophagus taken for approximately 10 minutes
Study: NCT05524285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial Support Catheter
Description: Endovascular procedure using the intracranial support catheter which approved by NMPA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guide Catheter
Description: Endovascular procedure using the guide catheter which approved by NMPA
Study: NCT05781841

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of expression of SOCS3 gene
Description: Detection of expression of SOCS3, in each samples using Real-Time PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of expression of SOCS3 gene
Description: Detection of expression of SOCS3, in each samples using Real-Time PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of expression of IFN-α gene
Description: Detection of expression of IFN-α gene in each samples using Real-Time PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of expression of IFN-α gene
Description: Detection of expression of IFN-α gene in each samples using Real-Time PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of expression of IFN-β gene
Description: Detection of expression of IFN-β gene in each samples using Real-Time PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of expression of IFN-β gene
Description: Detection of expression of IFN-β gene in each samples using Real-Time PCR
Study: NCT06142175

Intervention type: BIOLOGICAL
Intervention: Relmacabtagene Autoleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
Study: NCT05968027

Intervention type: OTHER
Intervention: Nouveal numeric application Onco'nect
Description: A remote monitoring application, Onco'nect® (smartphone /tablet /PC), in partnership with the company Nouveal facilitates communication between patients undergoing Intra Vascular (IV) chemotherapy and the care team. A questionnaire before and after each session can be used to alert the oncology department and adapt patient management.
Study: NCT04760288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Description: Participants will receive pralsetinib at a dose of 400 mg, as per the dosing schedule described above.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Adult participants will receive cabozantinib at a dose of 140 mg, as per the dosing schedule described above.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib
Description: Adult participants will receive vandetanib at a dose of 300 mg and adolescent participants will receive vandetanib as per the dosing schedule described above.
Study: NCT05820321

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice rich in nitrate
Description: The participant will intake beetroot juice rich in NO3 (400mg) during 8-days. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will return to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice NO3 depleted
Description: The participant will intake beetroot juice depleted in NO3. On the eighth day of the intervention, 2 hours after intake the last bottle of juice, the participants will to the laboratory for the performance tests evaluation. Before crossover protocol a 7-day washout interval will be given for the purification of the compounds provided by the protocols.
Study: NCT05615662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meru Health Program
Description: The Meru Health Program is a 12-week, evidence-based, smartphone-delivered, therapist-supported digital mental health intervention with as-needed psychiatrist oversight. Enrolled participants work through the program with a cohort of peers similarly affected by depression, with whom they can engage in confidential, anonymous, voluntary group chats overseen by a licensed clinical therapist. The MHP incorporates a continuous care model including daily interaction with a dedicated clinician, several evidence-based treatment components such as cognitive behavioral therapy (CBT), behavioral activation therapy, and mindfulness meditation (MM), as well as promising newer types of depression treatments such as HRVB, nutritional psychiatry, and sleep training. Practices are introduced to weekly topics via video lessons that are reinforced via CBT practices, meditations, and biofeedback sessions and therapist messaging.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual in this study will include all of the regular standards of care for mental health needs. These standards of care may include, but are not limited to psychotherapy, pharmacotherapy, or complementary therapy.
Study: NCT05950022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic tenotomy surgery of the iliopsoas tendon
Description: The surgery will be performed under general anesthesia with standardized multimodal analgesia. Whatever the techniques, the approaches, the instruments to perform the procedure and the postoperative course will be identical, as in usual practice.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic tenotomy surgery of the iliopsoas tendon
Description: The surgery will be performed under general anesthesia with standardized multimodal analgesia. Whatever the techniques, the approaches, the instruments to perform the procedure and the postoperative course will be identical, as in usual practice.
Study: NCT05979402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training group Face-to-face pressure ulcer training
Description: Face-to-face presure ulcer training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No intervention
Study: NCT05245084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386(3)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-386(3)
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326, D337
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326, D337
Description: QD, PO
Study: NCT05436145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study behavioral change mobile notification
Description: The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications include 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. All notifications are categorized as one of two types of message sets: 1) Support, or 2) Consequences. Within each message set the core content is adapted to provide either 1) Emotional Support or Practical Support, or 2) Gain or Loss-Framed Consequences.
Study: NCT05533645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: These patients complete the food frequency questionnaire in order to validate it for lower sodium consumptions. The experimental group has already received dietary advices regarding salt consumption during during their recent consultations.
Study: NCT06483269

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PRP infiltration
Description: a single intra-articular infiltration of 5 mL of PRP-O will be performed by the infiltrating physician.~It is specified that the PRP-O used within the study will be produced following the guidelines and standards for the production of blood products for non-transfusion use as already in place at the Unified Metropolitan Transfusion Service IOR site.~PRP (Platelet Rich Plasma) is produced from platelet pool from donor buffy coat.~PRP contains 1,000,000 PLT/mml +/- 20%, as required by current regulations.
Study: NCT05918419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: PD-1 antibody
Study: NCT04735770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine
Description: Postoperative pain management

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine
Description: Postoperative pain management
Study: NCT05651308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care coordination delivered based on perceived need
Description: If proxies for patients in intervention group report on the survey that they experience difficulty coordinating care among the patients' providers, the patient will be selected for care management services. Those services will attempt to address the problems with care coordination that the proxy reported.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care coordination delivered based on usual care (e.g. discharge from hospital)
Description: If a patient is discharged from a hospital, the patient will be selected for care management services.
Study: NCT05587868

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Mandatory COVID-19 vaccination as part of the the Indonesian national government program.

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Mandatory COVID-19 vaccination as part of the the Indonesian national government program.

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Mandatory COVID-19 vaccination as part of the the Indonesian national government program.
Study: NCT04840420

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: social prescribing
Description: as above

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: as above
Study: NCT05720026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYSA1901
Description: loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: loading dose of 840 mg IV, followed by 420 mg IV, q3w/cycle, total 4cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: loading dose of 8 mg/kg IV, followed by 6 mg/kg IV, q3w/cycle, total 4cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: loading dose of 8 mg/kg IV, followed by 6 mg/kg IV, q3w/cycle, total 4cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 IV, q3w/cycle, total 4cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 IV, q3w/cycle, total 4cycle
Study: NCT05426213

Intervention type: DEVICE
Group type: OTHER
Intervention: Robot-assisted Bronchoscopy (Monarch Platform)
Description: Robotic assisted bronchoscopy biopsy procedures will be performed using the Monarch platform.